Qorium
Qorium is the world’s leading cell-cultured leather company, having successfully produced a pioneering proof of concept product in 2021. Qorium’s leather comes with dramatically reduced carbon emissions, no methane emissions and radically reduced water and chemical use compared to traditional leather, with no ties to the livestock industry or the polluting processes necessary in the processing of animal hides.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Status
Live
Website
www.qorium.com
Related News
Bio-engineering scale-up Qorium showcases cultivated leather breakthrough, signaling a key step towards commercialisation
Qorium bolsters Board with appointment of Elizabeth Bastoni and Martin Brok, renowned experts in the consumer goods and retail sectors
Qorium lands additional funds from Brightlands Venture Partners and Sofinnova Partners, as the company sets out on an ambitious growth drive for sustainable leather with the appointment of CEO Michael Newton
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.